HIM
PACB icon

Hillsdale Investment Management’s Pacific Biosciences PACB Stock Holding History

Hillsdale Investment Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,400
Closed -$879K – 629
2021
Q1 		$879K Buy
+26,400
New +$924K 0.07% 265

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hillsdale Investment Management's PACB Position: Q2 2021 in Review

Hillsdale Investment Management sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 26,400 shares — an estimated $879K sold.

Hillsdale Investment Management first reported a position in PACB in Q1 2021 and held it in 1 quarter. The position peaked at $879K in Q1 2021. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

  • Hillsdale Investment Management reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 26,400 Pacific Biosciences shares in Q2 2021, an estimated $879K.
  • Hillsdale Investment Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 1 quarter.
  • Hillsdale Investment Management's Pacific Biosciences position peaked at $879K in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on Hillsdale Investment Management's 13F filing for Q2 2021, filed 29 Jul 2021.